arrow
G

George Dranitsaris

augmentium pharma consulting inc.
H指数:30
被引数:4,055

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Personalised Antiemetic Prophylaxis with NEPA for Patients at High-Risk of Chemotherapy-induced Nausea and Vomiting Receiving Moderately Emetogenic Chemotherapy: Results from the Randomised, Multinational MyRisk Trial

基于NEPA的个性化抗恶心预防方案用于接受中度致吐性化疗的高危化疗诱导恶心呕吐患者的疗效:随机、多国MyRisk试验结果

2025-10-170
PRE
Benralizumab for treatment of eosinophil-related cutaneous adverse events associated with checkpoint inhibitors and anticancer targeted therapies: Phase 2 study
2024-03-220
PRE
JAK inhibition reduces SARS-CoV-2 liver infectivity and modulates inflammatory responses to reduce morbidity and mortality

抑制JAK可降低SARS-CoV-2肝脏感染性并调节炎症反应,从而降低发病率和死亡率

2021-01-01162
OAAI